Pharmaceuticals

Daiichi Sankyo and Merck Initiate Phase 3 Study to Evaluate Safety and Efficacy of Ifinatamab Deruxtecan in Patients with Recurrent Small Cell Lung Cancer

bexib
By bexib 0 Min Read

IDeate-Lung02 will compare ifinatamab deruxtecan to physician’s choice of chemotherapy in patients with recurrent small cell lung cancer.

You Might Also Like

HDR UK and DPUK award £2 million to new Motor Neurone Disease research initiative

FDA approves Filspari for adult patients with IgA nephropathy

NHS to roll out fiber optic laser treatment to prevent seizures in epilepsy patients

FDA approves two Scientia Vascular neurovascular catheters

BHF HIF funds over £800,000 to five heart research projects

Share This Article
Previous Article Occupy Bitcoin: Bitcoin is not just libertarian
Next Article Asia FX firms bet on rate cut, yen hits 5-month high on hawkish BoJ stance Investing.com – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Progress of metal cutting technology: Innovative innovation, sustainability, and future labor
Manufacturing
Ceratizit showcases innovation, sustainability and cutting-edge solutions at IMTEX 2025
Manufacturing
Goldman launches an internal GEN AI Assistant with 10K employees
Banking
Taiwan emerges as key player in Indian machine tools market with 20.8% growth
Manufacturing